No need to stop ibrutinib in patients who develop AF

Atrial fibrillation related to ibrutinib treatment can be managed with standard measures  and DOACs without patients having to stop cancer treatment, experience at an Australian centre suggests. Ibrutinib-related AF was more common in real world practice than in the literature, according to a small cohort report by haematologists at the Hunter New England Health District. ...

Already a member?

Login to keep reading.

© 2021 the limbic